Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Physicians in the U.S. who Treat Chronic Obstructive Pulmonary Disease (COPD)(?)

Council Members in this Study Group: 192

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Warren Botnick, MD
President
PSS Clinical Research

Warren Botnick, MD, FCCP, DABSM, is a Partner at Pulmonary and Sleep Specialists in Decatur, Georgia, since March 2003. He is Director of Critical Care Unit and Chief of Medicine at DeKalb Medical Center, Medical Director of Southern Sleep Technologies, and Co-Director of two sleep disorders centers...

Robert Aris, MD, Associate Professor of Medicine, University of North Carolina Chapel Hill - CCRobert Aris, MD
Associate Professor of Medicine
University of North Carolina Chapel Hill - CC

Robert Aris, MD, is an Associate Professor of Medicine at the University of North Carolina Chapel Hill. He is the Director of the Pulmonary Hypertension Program, the Lung Transplant Research Program and Inpatient Pulmonary Services. Dr. Aris has expertise in advanced lung diseases including cystic...

Kamal Mubarak, MD
Assistant Professor & Director
University of Florida

Kamal Mubarak, MD, is an Assistant Professor and Director of the Pulmonary Vascular Disease Program at University of Florida, Gainesville. Dr. Mubarak's clinical specialties include Internal Medicine, Critical Care Medicine, and Pulmonary Disease. He is involved in numerous clinical trials in treating...

Michael Blaiss, MD, Partner, Allergy & Asthma CareMichael Blaiss, MD
Partner
Allergy & Asthma Care

Michael S. Blaiss, MD, is a Clinical Professor of Pediatrics and Medicine at University of Tennessee Health Sciences Center and in private practice at Allergy & Asthma Care in Memphis. Dr. Blaiss’s clinical focus is on allergies and has expertise in outcomes research in allergic disorders, especially...

Michael Wechsler, MD
Associate Physician in Pulmonary and Critical Care
BRIGHAM AND WOMEN'S HOSPITAL

Michael Wechsler, MD, is an Associate Physician in the Pulmonary and Critical Care Division of Brigham and Women's Hospital in Boston and is on the faculty at Harvard Medical School. He is a member of the Steering Committee of the NIH's Asthma Clinical Research Network and is active in both basic and...

Michael Kallay, MD
Associate Professor of Medicine
University Of Rochester Medical Center

Michael Kallay, MD, is Associate Professor of Medicine at the University of Rochester. His expertise is in asthma, exercise physiology and COPD, and interstitial lung diseases and his research interest in the management of interstitial lung diseases. Dr. Kallay has been a principal investigator in over...

David Engler, MD, Physician, The Allergy ClinicDavid Engler, MD
Physician
The Allergy Clinic

David Engler, MD, a graduate of Baylor College of Medicine, has worked at The Allergy Clinic since 1991. He has served two terms on the Board of Regents of the American College of Allergy, Asthma & Immunology, and has represented that organization at the A.M.A. Dr. Engler has a busy sub-specialty...

Mitchell Boxer, MD
Assistant Clinical Professor
Albert Einstein College of Medicine

Mitchell Boxer, MD, is Director of the Adult Allergy Section at Long Island Jewish Medical Center and Assistant Clinical Professor at Albert Einstein Medical College. Dr. Boxer completed his fellowship at Northwestern University Medical College and has expertise in a wide range of allergic and immunologic...

View all Leading Experts in this Study Group

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Minimal Impact on Stent Market | 08-21-2008
Author: GLG Expert Contributor

Because equivalent results were shown, there will be no change in stent placement volumes.

This makes a lot of cents... | 08-08-2008
Analysis of: Blood pressure drugs may protect against Alzheimer's | www.washingtonpost.com
Author: GLG Expert Contributor

I think that we primary care doctors have known all along that controlling several risk factors that we commonly see not only makes people live longer, but also more "intact" as they age.  I can look back over the last 28 years of practice and see that those patients who went downhill faster were...

Healthcare industry NOT immune to economic illness | 07-21-2008
Analysis of: Patients Curb Prescription Spending | online.wsj.com
Author: GLG Expert Contributor

The idea that people will always buy prescription and OTC drugs and will go to the physician and dentist, no matter what the economic conditions in the country, is, in my opinion, erroneous.  People's first priorities are getting to work (requiring gas), food, and shelter.  The most money...

Mild PAH improved by early treatment with bosentan | 07-18-2008
Author: Robert Aris, MD, Associate Professor of Medicine, University of North Carolina Chapel Hill - CC

While functional class II (FC II) PAH patients have been included in previous clinical trials, the EARLY trial is the first study to concentrate (ie recruit exclusively) FC II PAH patients.  This is important because the definition of functional class II is that a patient has a sight...

Yes - please stop the cycle of 70 deaths then pull the drug! | 07-03-2008
Author: GLG Expert Contributor

Drugs are released to the market without adequate study, then, after around 70 to 100 patient deaths due to the drug are reported, the drug is pulled from the market.  Getting in front of this "problem" would improve the safety of our drug supply.

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Director
  • Owner
  • Physician - Division Head
  • Director
  • Partner
  • Medical Director
  • President

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-09-05T13:45:17.290